Chung S.-D.HONG-JENG YU2021-02-022021-02-0220090929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-67649622959&doi=10.1016%2fS0929-6646%2809%2960078-4&partnerID=40&md5=e7e92391c540df185dba886422e2d8b5https://scholars.lib.ntu.edu.tw/handle/123456789/544206[SDGs]SDG35 [[(3 phenoxybenzyl)(1,2,3,4 tetrahydro 1 naphthyl)amino]carbonyl]trimellitic acid; alpha adrenergic receptor blocking agent; beta 3 adrenergic receptor stimulating agent; botulinum toxin A; capsaicin; cholinergic receptor blocking agent; endothelin 1; endothelin A receptor; endothelin B receptor; endothelin receptor antagonist; muscarinic receptor blocking agent; noradrenalin; phosphodiesterase V inhibitor; placebo; prostate specific antigen; purinergic P2X3 receptor; purinergic receptor blocking agent; resiniferatoxin; tamsulosin; tolterodine; vanilloid receptor 1; bladder capacity; bladder disease; chronic inflammation; clinical trial; dose response; drug efficacy; drug safety; drug targeting; human; lower urinary tract symptom; micturition; monotherapy; neuropathic pain; nonhuman; overactive bladder; prostate hypertrophy; receptor upregulation; short survey; spinal cord injury; treatment outcome; urge incontinence; urinary urgency; urodynamicsshort survey10.1016/S0929-6646(09)60078-42-s2.0-67649622959